A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
08/2011
08/18/2011	US20110200619 Pharmaceutical compounds as cytotoxic agents and uses thereof
08/18/2011	US20110200618 Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders
08/18/2011	US20110200617 Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
08/18/2011	US20110200616 Immunizing Compositions and Methods of Use
08/18/2011	US20110200615 Antibodies that Neutralize Botulinum Neurotoxins
08/18/2011	US20110200614 Anthrax specific antibodies
08/18/2011	US20110200613 Use of B Cell Expansion Agents in Generating Antibodies
08/18/2011	US20110200612 Treatment of eye diseases and excessive neovascularization using combined therapy
08/18/2011	US20110200611 Plasma kallikrein binding proteins
08/18/2011	US20110200610 Immuno-Modulating Compositions for the Treatment of Immune-Mediated Disorders
08/18/2011	US20110200609 Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
08/18/2011	US20110200608 Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
08/18/2011	US20110200607 Binding Proteins Specific for Insulin-Like Growth Factors and uses Thereof
08/18/2011	US20110200606 Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor
08/18/2011	US20110200605 Polypeptides and use thereof
08/18/2011	US20110200604 IDENTIFICATION OF NOVEL IgE EPITOPES
08/18/2011	US20110200603 New antigens for paratuberculosis diagnosis and vaccination
08/18/2011	US20110200602 Antibodies to egfl7 and methods for their use
08/18/2011	US20110200601 Drug Delivery to Human Tissues by Single Chain Variable Region Antibody Fragments Cloned by Phage Display
08/18/2011	US20110200600 Diagnosis and prognosis of immune disorders using stat4 expression
08/18/2011	US20110200599 Sustained drug delivery system
08/18/2011	US20110200598 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
08/18/2011	US20110200597 Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
08/18/2011	US20110200596 Monovalent antibody fragments useful as therapeutics
08/18/2011	US20110200595 TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
08/18/2011	US20110200594 Functionalized polypeptides
08/18/2011	US20110200593 Combination Therapy for the Treatment of Ocular Neovascular Disorders
08/18/2011	US20110200592 Methods For Reducing Viral Load in HIV-1 Infected Patients
08/18/2011	US20110200591 Products and methods to prevent infections
08/18/2011	US20110200590 Antibodies Directed Against the Myelin Basic Protein Recognising an Epitope of CD64 and Their Use as Immunosuppressants
08/18/2011	US20110200589 Deconvolution method
08/18/2011	US20110200588 Methods for genetic analysis
08/18/2011	US20110200587 Aminothiazolones as estrogen related receptor-alpha modulators
08/18/2011	US20110200586 Aminothiazolones as estrogen related receptor-alpha modulators
08/18/2011	US20110200585 Cd127 binding proteins
08/18/2011	US20110200584 Method to stimulate immune function and regeneration
08/18/2011	US20110200583 Asthma Susceptibility Loci Located at Chromosome 1q31 for Use in Diagnostic and Therapeutic Methods
08/18/2011	US20110200582 Lipids, lipid compositions, and methods of using them
08/18/2011	US20110200581 Pharmaceutical compositions
08/18/2011	US20110200580 Methods of treatment and prevention of diet-induced obesity and sequelae thereof
08/18/2011	US20110200579 Novel gene disruptions, compositions and methods relating thereto
08/18/2011	US20110200557 New 2-amidothiadiazole derivatives
08/18/2011	US20110200556 Chemoprevention of head and neck squamous cell carcinomas
08/18/2011	US20110200530 Targeting construct comprising anti-polymer antibody and contrast/therapeutic agents binding to the same
08/18/2011	US20110200525 Vhh antibody fragments for use in the detection and treatment of cancer
08/18/2011	US20110200524 Vector for use in medicine
08/18/2011	CA2789629A1 Cd20 antibodies and uses thereof
08/18/2011	CA2789623A1 Therapeutic methods using anti-cd200 antibodies
08/18/2011	CA2789505A1 Free hexasaccharide isolated from several campylobacter species
08/18/2011	CA2789485A1 Compositions and methods for the treatment of cardiac and vascular disease
08/18/2011	CA2789446A1 Methods for identifying and isolating cells expressing a polypeptide
08/18/2011	CA2789436A1 Upar binding agents and methods of use thereof
08/18/2011	CA2789432A1 Serologic correlates of protection against bacillis anthracis infection
08/18/2011	CA2789416A1 Novel uses
08/18/2011	CA2789353A1 Peptides for vaccines against birch allergy
08/18/2011	CA2789328A1 Multimeric proteins comprising immunoglobulin constant domains
08/18/2011	CA2789310A1 Radioactive metal-labeled anti-cadherin antibody
08/18/2011	CA2789251A1 Agonist dr5 binding polypeptides
08/18/2011	CA2789174A1 Process for producing an allergen extract
08/18/2011	CA2788972A1 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
08/18/2011	CA2788758A1 Treatment of a metabolic disorder
08/18/2011	CA2788680A1 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
08/18/2011	CA2788400A1 Antibodies against cxcr4
08/17/2011	EP2357238A2 Compositions and methods for regulation of tumor necrosis factor-alpha
08/17/2011	EP2357231A2 Stabilized immune modulatory RNA (SIMRA) compounds
08/17/2011	EP2357202A1 Targeted binding agents directed to Upar and uses thereof
08/17/2011	EP2357201A1 Anti-P-selectin antibodies
08/17/2011	EP2357200A1 Human antibodies that bind human TNFalpha
08/17/2011	EP2357198A1 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
08/17/2011	EP2357196A2 Immunoglobulin chimeric monomer-dimer hybrids
08/17/2011	EP2357187A1 Molecules with extended half-lives, compositions and uses thereof
08/17/2011	EP2357009A1 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
08/17/2011	EP2357008A1 Albumin fusion proteins
08/17/2011	EP2357005A1 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
08/17/2011	EP2357004A1 NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods
08/17/2011	EP2357003A2 Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression
08/17/2011	EP2357002A1 Nucleic acid molecules and polypeptides for immune modulation
08/17/2011	EP2357001A1 Regimens for immunisation with meningococcal conjugates
08/17/2011	EP2357000A1 Mucosal and systemic immunizations with alphavirus replicon particles
08/17/2011	EP2356999A1 Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
08/17/2011	EP2356996A1 Treatment for Alzeimer's disease
08/17/2011	EP2356994A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/17/2011	EP2356983A1 Circulation of components during homogenization of emulsions
08/17/2011	EP2356238A2 Nurr1 interacting protein (nuip)
08/17/2011	EP2356225A1 GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
08/17/2011	EP2356224A1 Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
08/17/2011	EP2356152A1 Anti-tgf-beta receptor ii antibodies
08/17/2011	EP2356147A1 Polypeptides, antibody variable domains&antagonists
08/17/2011	EP2356144A2 Composition for producing anti-amyloid beta peptide antibodies with d-peptides
08/17/2011	EP2356133A2 Recombinant protein bodies as immunogen-specific adjuvants
08/17/2011	EP2356132A2 Torque teno virus (ttv) isolates and compositions
08/17/2011	EP2355850A2 N-cadherin: target for cancer diagnosis and therapy
08/17/2011	EP2355849A1 Methods of improving the therapeutic efficacy and utility of antibody fragments
08/17/2011	EP2355848A2 Blockers of light, ltalpha1beta2 and ltalpha2beta1 or their receptor ltbetar for the prevention and treatment of chronic hepatitis and other liver diseases
08/17/2011	EP2355847A1 Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
08/17/2011	EP2355846A2 Immunogenic escherichia coli heat stable enterotoxin
08/17/2011	EP2355845A1 Vaccine compositions comprising a mutated factor h binding protein
08/17/2011	EP2355844A2 Eimeria vaccine for turkeys
08/17/2011	EP2355843A1 Vaccine for the prevention of breast cancer recurrence
08/17/2011	EP2355842A1 Priming of an immune response

1 ... 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 ... 1823